Jobs
-
According to Optinose, the Phase 3 ReOpen1 trial of Xhance intranasal fluticasone propionate (OPN-375) in patients with chronic sinusitus met both of its primary endpoints, demonstrating statistically significant reduction in symptoms and in sinus inflammation… Read more . . .
-
Tonix Pharmaceuticals has provided updates on two formulations of its intranasal potentiated oxytocin. The company acquired the license for one of the formulations, TNX-1900 for the treatment of migraine, from Trigemina in June 2020. According… Read more . . .
-
Device maker HCmed Innovations has partnered with Formosa Laboratories and Formosa Pharmaceuticals to offer contract development and manufacturing services for inhaled drugs, HCmed announced. Formosa Laboratories already offers CDMO services for pharmaceutical products; the new… Read more . . .
-
In December 2021, inhaled drug developer Aerami Therapeutics announced that it would go public by merging with FoxWayne Enterprises Acquisition Corp, a special purpose acquisition company (SPAC). The two companies have now announced that the deal… Read more . . .
-
According to Medical Developments International (MVP), the FDA has lifted a clinical hold on MVP’s Penthrox methoxyflurane inhaler and, as a result, MVP is now preparing a Phase 3 trial of Penthrox for trauma pain… Read more . . .
-
Sorrento Therapeutics announced that the FDA has given the company the okay to move ahead with a Phase 1 trial of its Covishield (STI-9199) intranasal antibody cocktail in healthy volunteers. According to Sorrento, in vitro… Read more . . .
-
BlueWillow Biologics and Medigen Vaccine Biologics Corporation (MVC) have announced that a preclinical study of their BW-1019 intranasal COVID-19 booster demonstrated that giving the nasal vaccine after intramuscular vaccination induced neutralizing antibodies and protected against disease in… Read more . . .
-
Non-profit pharma company Harm Reduction Therapeutics (HRT) said that a Phase 1 clinical trial of its HRT001 naloxone nasal spray in healthy volunteers met its primary endpoint, demonstrating the bioequivalence of a 3.0 mg dose… Read more . . .
-
Broughton, a CRO that offers development and analysis of inhaled drugs, especially nicotine and cannabinoid products, has announced the establishment of a US subsidiary. Tony Jones, who has most recently been Senior Managing Health Scientist… Read more . . .
-
DPI developer Pulmatrix has hired Margaret Wasilewski as its Chief Medical Officer, the company said. Wasilewski most recently offered consulting services as President of ID Remedies, and her previous experience includes clinical development positions at… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK